MAPK1 and hepatocellular carcinoma: Together, these results suggest the possibility of using the inhibitors of the ERK/MAPK signaling pathway as MDR reversal agents, thus providing evidence for the use of these inhibitors in combination with traditional chemotherapeutic drugs in treating HCC patients.